Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2020 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Olliges E, Bührlen B, Fischer F, Boesecke C, Kümmerle T, Schneider J, Weidlich S, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen BE, Wolf E, Ronel J, Spinner CD, On Behalf Of The Dualis Study Group. Olliges E, et al. AIDS Care. 2022 Jun;34(6):698-707. doi: 10.1080/09540121.2021.1916873. Epub 2021 Apr 25. AIDS Care. 2022. PMID: 33896276 Clinical Trial.
Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes.
Monin M, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Balogh A, Wolf E, Bidner H, Spinner CD, Boesecke C; DUALIS STUDY GROUP. Monin M, et al. HIV Res Clin Pract. 2021 Dec 23;23(1):15-21. Epub 2022 Mar 2. HIV Res Clin Pract. 2021. PMID: 35234092 Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.
Spinner CD, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Wyen C, Viehweger M, Lehmann C, Sprinzl M, Stoehr A, Bickel M, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Wolf E, Boesecke C; DUALIS Study Group. Spinner CD, et al. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. doi: 10.1093/ofid/ofaa356. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 32965277 Free PMC article.